Impact of molecular diagnostic tests on diagnostic and treatment delays in tuberculosis: a systematic review and meta-analysis

Abstract

Background Countries with high TB burden have expanded access to molecular diagnostic tests. However, their impact on reducing delays in TB diagnosis and treatment has not been assessed. Our primary aim was to summarize the quantitative evidence on the impact of nucleic acid amplification tests (NAAT) on diagnostic and treatment delays compared to that of the standard of care for drug-sensitive and drug-resistant tuberculosis (DS-TB and DR-TB). Methods We searched MEDLINE, EMBASE, Web of Science, and the Global Health databases (from their inception to October 12, 2020) and extracted time delay data for each test. We then analysed the diagnostic and treatment initiation delay separately for DS-TB and DR-TB by comparing smear vs Xpert for DS-TB and culture drug sensitivity testing (DST) vs line probe assay (LPA) for DR-TB. We conducted random effects meta-analyses of differences of the medians to quantify the difference in diagnostic and treatment initiation delay, and we investigated heterogeneity in effect estimates based on the period the test was used in, empiric treatment rate, HIV prevalence, healthcare level, and study design. We also evaluated methodological differences in assessing time delays. Results A total of 45 studies were included in this review (DS = 26; DR = 20). We found considerable heterogeneity in the definition and reporting of time delays across the studies. For DS-TB, the use of Xpert reduced diagnostic delay by 1.79 days (95% CI − 0.27 to 3.85) and treatment initiation delay by 2.55 days (95% CI 0.54–4.56) in comparison to sputum microscopy. For DR-TB, use of LPAs reduced diagnostic delay by 40.09 days (95% CI 26.82–53.37) and treatment initiation delay by 45.32 days (95% CI 30.27–60.37) in comparison to any culture DST methods. Conclusions Our findings indicate that the use of World Health Organization recommended diagnostics for TB reduced delays in diagnosing and initiating TB treatment. Future studies evaluating performance and impact of diagnostics should consider reporting time delay estimates based on the standardized reporting framework.

Analysis of care-seeking and diagnosis delay among pulmonary tuberculosis patients in Beijing, China

“…Compared to conventional methods for pathogen detection, GeneXpert offers the advantages of rapid detection speed and high accuracy (positive results can be detected when the number of M.tb is >130/mL) ( 41 ). According to a report, the use of GeneXpert reduced diagnostic delay by 1.79 days (95% CI: 0.27–3.85) and treatment initiation delay by 2.55 days (95% CI: 0.54–4.56) compared to sputum microscopy ( 42 ). Currently, GeneXpert technology is only available in certain designated tuberculosis hospitals in China.…”

Delays in health seeking, diagnosis and treatment for tuberculosis patients in Mongolia: an analysis of surveillance data, 2018–2021

“…Such spatial heterogeneity is common in many countries regardless of income level, and multiple studies have shown that living in a rural area is associated with longer health-seeking delays. ( 4 , 12 , 16 ) Increasing access to health care through initiatives that deliver more patient-centred services (e.g. use of mobile teams in rural areas, adopting clinic opening hours that match patients’ preferences) has proven to reduce delays in health seeking.…”

Strengthening diagnostic capacity in Africa as a key pillar of public health and pandemic preparedness

“…Rapid point of care and self-administered testing kits for HIV which can deliver a result within minutes have reduced costs in testing and improved linkage to HIV care [ 9 , 10 ]. Similarly for TB, the widespread implementation of rapid molecular testing which is recommended by the World Health Organization, has led to reduced delays in diagnosis and treatment initiation [ 11 ]. There is an opportunity to build on these achievements to develop rapid diagnostic tests for other pathogens with pandemic and outbreak potential–indeed, to support COVID-19 diagnostic testing, countries employed existing HIV and TB molecular testing platforms.…”